Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 4
1976 4
1977 2
1980 2
1982 1
1984 1
1986 1
1989 4
1991 2
1992 1
1993 4
1994 2
1995 1
1996 2
1999 1
2000 1
2001 4
2002 4
2003 4
2004 2
2005 3
2006 3
2007 5
2008 4
2009 6
2010 4
2011 5
2012 4
2013 1
2014 2
2015 14
2016 7
2017 8
2018 6
2019 7
2020 6
2021 6
2022 3
2023 4
2024 4
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.
Colorectal Cancer OncoGuia.
Manchon Walsh P, Borràs JM, Ferro T, Espinàs JA; Colorectal Cancer OncoGuia Group. Manchon Walsh P, et al. Clin Transl Oncol. 2010 Mar;12(3):188-210. doi: 10.1007/s12094-010-0489-5. Clin Transl Oncol. 2010. PMID: 20231124 No abstract available.
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance.
Martinez-Balibrea E, Martínez-Cardús A, Ginés A, Ruiz de Porras V, Moutinho C, Layos L, Manzano JL, Bugés C, Bystrup S, Esteller M, Abad A. Martinez-Balibrea E, et al. Among authors: manzano jl. Mol Cancer Ther. 2015 Aug;14(8):1767-76. doi: 10.1158/1535-7163.MCT-14-0636. Epub 2015 Jul 16. Mol Cancer Ther. 2015. PMID: 26184483 Review.
Resistant mechanisms to BRAF inhibitors in melanoma.
Manzano JL, Layos L, Bugés C, de Los Llanos Gil M, Vila L, Martínez-Balibrea E, Martínez-Cardús A. Manzano JL, et al. Ann Transl Med. 2016 Jun;4(12):237. doi: 10.21037/atm.2016.06.07. Ann Transl Med. 2016. PMID: 27429963 Free PMC article. Review.
Development of morphea during Nivolumab treatment.
Fabregat-Pratdepadua M, Boada A, Manzano JL, Bielsa I, Verdaguer-Faja J, Quer Pi-Sunyer A, Carrascosa JM. Fabregat-Pratdepadua M, et al. Among authors: manzano jl. Australas J Dermatol. 2022 May;63(2):269-271. doi: 10.1111/ajd.13834. Epub 2022 Mar 24. Australas J Dermatol. 2022. PMID: 35325471 No abstract available.
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM).
Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, Podzamczer D, Manzano JL, Molto J, Revollo B, Carrera C, Mateu L, Fancelli S, Espinosa E, Clotet B, Martinez-Picado J, Cerezuela P, Soria A, Marquez I, Mandala M, Berrocal A; Spanish Melanoma Group (GEM). Gonzalez-Cao M, et al. Among authors: manzano jl. J Immunother Cancer. 2021 Mar;9(3):e001664. doi: 10.1136/jitc-2020-001664. J Immunother Cancer. 2021. PMID: 33782108 Free PMC article. Review.
Determinants of response and resistance to cytotoxics.
Rosell R, Monzó M, Alberola V, Taron M, Barnadas A, Sánchez JM, Manzano JL, Sanchez JJ. Rosell R, et al. Among authors: manzano jl. Semin Oncol. 2002 Feb;29(1 Suppl 4):110-8. doi: 10.1053/sonc.2002.31532. Semin Oncol. 2002. PMID: 11894021 Review.
147 results